DOM-WT1-37 + DOM-WT1-126

Combination of two DNA vaccines encoding Wilms’ tumor 1 (WT1) epitopes fused to a helper domain (DOM) and delivered by intramuscular injection followed by electroporation to induce WT1-specific cellular and humoral immunity in hematologic malignancies, primarily chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Developed in collaboration by the University of Southampton and Inovio, the regimen consists of six initial doses at four-week intervals with optional boosters every three months up to 24 months. Clinical studies reported robust WT1-specific antibody and T-cell responses and acceptable safety; limited clinical molecular responses were observed in a small CML cohort, and the CML arm did not complete recruitment. The approach remains of interest for AML but was noted as unlikely to be feasible at the time of reporting without combination strategies to amplify T-cell responses.[4][1][2][9]

Other names

WT1 DNA vaccine combinationWT-1 DNA vaccine combinationWT 1 DNA vaccine combinationWT1 fusion gene DNA vaccinesWT-1 fusion gene DNA vaccinesWT 1 fusion gene DNA vaccines